Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Convertible Debt (2020)

Barinthus Biotherapeutics (BRNS) has disclosed Convertible Debt for 1 consecutive years, with $44.7 million as the latest value for Q4 2020.

  • For the quarter ending Q4 2020, Convertible Debt changed N/A year-over-year to $44.7 million, compared with a TTM value of $44.7 million through Dec 2020, changed N/A, and an annual FY2020 reading of $44.7 million, changed N/A over the prior year.
  • Convertible Debt was $44.7 million for Q4 2020 at Barinthus Biotherapeutics.
  • Across five years, Convertible Debt topped out at $44.7 million in Q4 2020 and bottomed at $44.7 million in Q4 2020.